Wegovy is a glucagon-like peptide-1 receptor agonist (also called a GLP-1 medication) that has been approved by the Food and Drug Administration (FDA) for the following indications: to help with weight loss and long-term weight management in certain adults and children who are overweight or have obesity to reduce the risk of major adverse cardiovascular (CV) events (heart attack, stroke, or CV death) in adults with established cardiovascular disease who are overweight or have obesity to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis Wegovy is typically prescribed as part of a treatment plan that includes a healthy, reduced-calorie diet and regular exercise
For your safety and well-being, its important to seek professional guidance before beginning any new medication or weight loss plan
Some patients need more frequent monitoring if they have complex health conditions or experience issues with the medication
Clear insurance policies and wider access could help more people stay on semaglutide and get the full benefits of the treatment
When I evaluate Ozempic face or Wegovy face , I look at facial volume, tissue descent, skin quality, facial proportion, and the way your features have changed after weight loss
